Exosome complex

Exosome Technologies Market Research Report 2021 - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast to 2031 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021
Health, Biotechnology, Branches of biology, Business process, Exosome complex, RNA, Ribonucleases, Exosome, Compound annual growth rate, Forecast period, Market research

The "Exosome Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Exosome Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
  • The report on the global exosome technologies market studies past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031.
  • The report provides revenue of the global exosome technologies market for the period 2017-2031, considering 2020 as the base year and 2031 as the forecast year.
  • The report also provides the compound annual growth rate (CAGR) for the global exosome technologies market during the forecast period.

Coya Therapeutics to Participate at the LifeSci Partners Summer Symposium

Retrieved on: 
Wednesday, July 14, 2021
Branches of biology, Biology, Immune system, T cells, Immunology, Regulatory T cell, Coya, Exosome complex

HOUSTON, July 14, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced that Howard Berman, Ph.D., Chief Executive Officer of Coya Therapeutics, will provide a corporate update at the LifeSci Partners Summer Symposium on Wednesday, July 21, 2021, at 10:30 a.m.

Key Points: 
  • HOUSTON, July 14, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced that Howard Berman, Ph.D., Chief Executive Officer of Coya Therapeutics, will provide a corporate update at the LifeSci Partners Summer Symposium on Wednesday, July 21, 2021, at 10:30 a.m.
  • To register in advance for the presentation, please click here .
  • The presentation and archived webcast will also be accessible under Events in the news section of Coya website .
  • Headquartered in Houston, TX, Coya Therapeutics (TM) is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells (Tregs) to target disease.

Codiak BioSciences Appoints Anne-Virginie Eggimann, M.Sc., to Board of Directors

Retrieved on: 
Thursday, May 20, 2021
Life sciences, Biotechnology, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Exosome complex

b'CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today it has appointed Anne-Virginie Eggimann, M.Sc., to its board of directors.

Key Points: 
  • b'CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today it has appointed Anne-Virginie Eggimann, M.Sc., to its board of directors.
  • \xe2\x80\x9cHer perspectives and experience working with regulatory authorities to bring new platform technologies to market will be invaluable as we chart our next stage of growth building Codiak as a fully integrated biopharmaceutical company.\xe2\x80\x9d\nMs.
  • During her decade with Voisin, she contributed to the organization\xe2\x80\x99s global growth from three employees to more than 70.
  • All information in this press release is current as of the date of this report, and Codiak undertakes no duty to update this information unless required by law.\n'

Coya Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit

Retrieved on: 
Friday, May 14, 2021
Branches of biology, Regulatory T cell, Exosome complex, Dementia

b'Headquartered in Houston, TX, Coya Therapeutics\xe2\x84\xa2 is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells (Tregs) to target disease.

Key Points: 
  • b'Headquartered in Houston, TX, Coya Therapeutics\xe2\x84\xa2 is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells (Tregs) to target disease.
  • The company\xe2\x80\x99s CTreg\xe2\x84\xa2 (Cryopreservation for Tregs) system is patent pending and the first in the industry to overcome prior limitations of Treg cell therapies, allowing for serial infusions from a single manufacturing round.
  • Through our proprietary TAI\xe2\x84\xa2 (Tregs Against Inflammation\xe2\x84\xa2) and patent pending iscEXO\xe2\x84\xa2\xc2\xa0(immunosuppressive cell Exosome) platforms, Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patients with ALS, Frontotemporal Dementia, Parkinson\xe2\x80\x99s, Alzheimer\xe2\x80\x99s, and autoimmune diseases.
  • For more information, please visit www.coyatherapeutics.com\n'

Coya Therapeutics to Present at the B. Riley Securities’ Virtual Neuroscience Conference

Retrieved on: 
Tuesday, April 27, 2021
Branches of biology, Regulatory T cell, Exosome complex, Dementia, Branches of biology, Regulatory T cell, Exosome complex, Dementia, Branches of biology, Regulatory T cell, Exosome complex, Dementia

b'Headquartered in Houston, TX, Coya Therapeutics\xe2\x84\xa2 is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells (Tregs) to target disease.

Key Points: 
  • b'Headquartered in Houston, TX, Coya Therapeutics\xe2\x84\xa2 is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells (Tregs) to target disease.
  • The company\xe2\x80\x99s CTreg\xe2\x84\xa2 (Cryopreservation for Tregs) system is patent pending and the first in the industry to overcome prior limitations of Treg cell therapies, allowing for serial infusions from a single manufacturing round.
  • Through our proprietary TAI\xe2\x84\xa2 (Tregs Against Inflammation\xe2\x84\xa2) and patent pending iscEXOTM (immunosuppressive cell Exosome) platforms, Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patients with ALS, Frontotemporal Dementia, Parkinson\xe2\x80\x99s, Alzheimer\xe2\x80\x99s, and autoimmune diseases.
  • For more information, please visit www.coyatherapeutics.com\n'

Coya Therapeutics™ Announces Formation of Scientific Advisory Board

Retrieved on: 
Tuesday, February 23, 2021
Branches of biology, Regulatory T cell, Exosome complex, Biology

HOUSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc., (Coya), a clinical-stage biotechnology company developing first-in-class approaches that utilize autologous regulatory T cells (Tregs) and allogeneic exosome therapeutics for neurodegenerative and autoimmune diseases, today announced the formation of a Scientific Advisory Board (SAB).

Key Points: 
  • HOUSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc., (Coya), a clinical-stage biotechnology company developing first-in-class approaches that utilize autologous regulatory T cells (Tregs) and allogeneic exosome therapeutics for neurodegenerative and autoimmune diseases, today announced the formation of a Scientific Advisory Board (SAB).
  • We are excited and privileged to have the opportunity to work alongside this group of luminaries in the development of Coyas Treg modifying therapeutics for neurodegenerative and autoimmune diseases, said Howard Berman, Ph.D., CEO of Coya Therapeutics.
  • Dr Appels seminal research documented the intimate relationship of neurodegeneration and ALS progression with dysfunctional and decreased levels of Tregs.
  • Headquartered in Houston, TX, Coya Therapeutics is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells (Tregs) to target disease.

Codiak Reports Additional Positive Phase 1 Results for exoIL-12™ Confirming Local Pharmacology and Dose Selection for Safety and Efficacy Trial in Early-Stage Cutaneous T Cell Lymphoma (CTCL) Patients

Retrieved on: 
Thursday, February 4, 2021
Dose, Toxicology, Drugs, Exosome complex, Branches of biology, Organic compounds

IL-12 was not detected in plasma at any dose of exoIL-12 tested and plasma IP-10 was only detectable at the highest, 12 g dose.

Key Points: 
  • IL-12 was not detected in plasma at any dose of exoIL-12 tested and plasma IP-10 was only detectable at the highest, 12 g dose.
  • exoIL-12 is the first engineered exosome therapeutic candidate to be evaluated in humans and one of two Codiak programs currently in clinical development.
  • Each cohort received a subcutaneously administered single ascending dose of exoIL-12: 0.3 g, 1.0 g, 3.0 g, 6.0 g or 12.0 g, respectively.
  • Results showed detectable IL-12 near the injection site as much as 24 hours post injection at the 6 g dose.

Codiak BioSciences Reports Third Quarter 2020 Financial Results and Operational Progress

Retrieved on: 
Thursday, November 19, 2020
Branches of biology, Asset, Cash, Cash and cash equivalents, Exosome complex, Exosome, Biology

Human clinical testing now underway with Codiaks first two candidates, exoIL-12 and exoSTING

Key Points: 
  • Human clinical testing now underway with Codiaks first two candidates, exoIL-12 and exoSTING
    CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics, today reported third quarter 2020 financial results and operational progress.
  • Net loss for the quarter ended September 30, 2020 was $35.3 million, compared to a net loss of $20.7 million for the same period in 2019.
  • Research and development expenses were $30.7 million for the quarter ended September 30, 2020 compared to $16.5 million for the same period in 2019.
  • As of September 30, 2020, Codiak had cash, cash equivalents, and marketable securities of $48.3 million.

Bio-Techne And Hall Of Famer Cal Ripken Jr -Announce Partnership To Raise Awareness And Education To Empower Men With Prostate Cancer

Retrieved on: 
Tuesday, September 8, 2020
Prostate cancer, Anatomy, Branches of biology, Cancer, Prostate, Exosome complex, Prostate Cancer Foundation, ZERO—The End of Prostate Cancer

Recently the 21-year Major League veteran divulged that earlier this year he was diagnosedwith and successfully treated for prostate cancer.

Key Points: 
  • Recently the 21-year Major League veteran divulged that earlier this year he was diagnosedwith and successfully treated for prostate cancer.
  • Today Ripken, 60, is leading a national effort with Exosome Diagnostics to build education and awareness of the ExoDx Prostate test, encouragemen to proactively take action and be awareoftheir prostate health.
  • The ExoDx Prostate (EPI) test played an important role in the management of Cal's prostate cancer.
  • Currently, nearly 3.6 million American men are living with the disease only slightly less than the population of Los Angeles.

Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 6, 2020
Branches of biology, Exosome complex, RNA, Ribonucleases, Exosome, Forward-looking statement, Food and Drug Administration

-Plan to Initiate Study in Third Quarter, Subject to FDA Approval-

Key Points: 
  • -Plan to Initiate Study in Third Quarter, Subject to FDA Approval-
    -To Host Conference Call and Webcast Today at 4:30 p.m. ET-
    LOS ANGELES, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (Capricor) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today its financial results for the second quarter ending June 30, 2020 and provided a corporate update.
  • We had a very successful first half of 2020, marked by continued achievements in our expanding cell and exosome programs.
  • We are moving forward as quickly as possible with the goal of bringing a vaccine into the clinic.
  • All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.